NextCure (NASDAQ:NXTC) Rating Lowered to Sell at Wall Street Zen

NextCure (NASDAQ:NXTC) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

NXTC has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of NextCure in a report on Wednesday. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, NextCure currently has an average rating of “Hold” and a consensus target price of $19.00.

NextCure Stock Performance

Shares of NASDAQ NXTC opened at $5.99 on Friday. The business has a 50 day simple moving average of $4.43 and a 200 day simple moving average of $9.27. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The stock has a market cap of $21.62 million, a price-to-earnings ratio of -0.35 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, analysts predict that NextCure will post -7.89 EPS for the current year.

Institutional Investors Weigh In On NextCure

A number of large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter valued at approximately $160,000. Millennium Management LLC acquired a new position in NextCure in the 4th quarter valued at $185,000. Geode Capital Management LLC raised its holdings in NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the period. Renaissance Technologies LLC lifted its position in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in NextCure during the fourth quarter valued at about $988,000. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.